سعر ماليجنوميد 50مجم 28 قرص 2025

Malignomide bicalutamide 50 mg film-coated tablets, 28 tablets (4 strips), non-steroidal antiandrogen for prostate cancer by Hikma Specialized Pharmaceuticals (Egypt).

• Stage D2 metastatic carcinoma of the prostate, in combination with an LHRH analogue (50 mg daily); 150 mg daily is not approvedPopulation: Adult menDailyMed (U.S. National Library of Medicine)

• With an LHRH analogue (> 10%): hot flashes (most frequent, 53%), pain (general, back, pelvic, abdominal), asthenia, constipation, infection, nausea, peripheral oedema, dyspnoea, diarrhoea, haematuria, nocturia and anaemia.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to bicalutamide or any tablet component (angioneurotic oedema and urticaria have been reported).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Women: bicalutamide has no indication for women and should not be used in this population.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Pregnancy: can cause fetal harm.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hepatitis: severe liver injury and fatal hepatic failure have been reported, generally within the first 3-4 months; measure serum transaminases before starting, at regular intervals for the first four months, and periodically thereafter; discontinue if jaundice or ALT > 2x ULN.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Gynecomastia and breast pain were reported in up to 38% and 39% of patients with bicalutamide 150 mg as a single agent.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• LHRH agonists reduce glucose tolerance in males; consider monitoring blood glucose in patients receiving bicalutamide with an LHRH agonist. Monitor PSA and evaluate for clinical progression if PSA rises.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Coumarin anticoagulants (e.g. warfarin)Bicalutamide can displace coumarin anticoagulants from protein binding; serious bleeding has been reported - closely monitor PT/INR and adjust the anticoagulant dose.DailyMed (U.S. National Library of Medicine)
• CYP3A4 substrates (e.g. midazolam)R-bicalutamide inhibits CYP3A4 (midazolam AUC increased about 1.9-fold); use caution with CYP3A4 substrates.DailyMed (U.S. National Library of Medicine)

• Contraindicated in pregnancy (can cause fetal harm) and not indicated in females. Men with female partners of reproductive potential should use effective contraception during treatment and for 130 days after the final dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Not indicated in women; no information on presence in human milk (detected in rat milk).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Bicalutamide: Non-steroidal androgen receptor inhibitor that competitively inhibits the action of androgens by binding to cytosol androgen receptors in target tissue; prostatic carcinoma is androgen sensitive (US label).